The histological transformation into small cell or sarcomatoid lung cancer phenotypes, aberrations of drug transporters, or lysosomal sequestration (11) has been reported for the mechanisms underlying the diminished efficacy of EGFR TKI. The gene discussed is EGFR; the disease is lung cancer.